Physician profile
Jody Abrams
NPI 1942229844
$474,676.79
in general payments reported to CMS, 2019-2025
35 companies · $112K in 2025
The $112K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,137 · 2020: $8,213 · 2021: $55K · 2022: $97K · 2023: $106K · 2024: $89K · 2025: $112K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $115K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Travel and Lodging: $33K · Consulting Fee: $32K · Food and Beverage: $13K · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $115,162.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,400.00 |
| Travel and Lodging | $32,980.70 |
| Consulting Fee | $31,987.50 |
| Food and Beverage | $13,253.04 |
| Education | $113.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $261,771.01 | 2019-2023 | Tepezza |
| Amgen INC. | $172,258.22 | 2019-2025 | Tepezza, Uplizna |
| Ani Pharmaceuticals, INC. | $26,458.27 | 2023-2025 | Purified Cortrophin Gel, Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $6,374.03 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $1,537.97 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $1,242.56 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Biohaven Pharmaceuticals, INC. | $648.97 | 2020-2021 | |
| Allergan, INC. | $551.59 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $511.39 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $438.37 | 2021-2025 | Cequa |
| Pfizer INC. | $404.71 | 2023-2025 | |
| Biogen, INC. | $332.31 | 2019-2023 | Vumerity |
| Argenx US, INC. | $242.72 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $239.95 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $196.49 | 2019-2024 | Eylea, Eylea Hd |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $152.20 | 2023-2025 | Zilbrysq |
| Genzyme Corporation | $137.50 | 2019-2025 | |
| Genentech USA, INC. | $133.60 | 2021-2024 | Vabysmo |
| Merz Pharmaceuticals, LLC | $133.34 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $130.62 | 2022 | |
| Alcon Vision LLC | $119.75 | 2022-2025 | Rocklatan |
| Novartis Pharmaceuticals Corporation | $114.99 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $97.99 | 2023 | Acthar |
| Shire North American Group INC | $92.12 | 2019 | |
| Harrow Eye, LLC | $69.35 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $56.87 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $50.73 | 2023-2025 | Tecnis Iol |
| Alimera Sciences, INC. | $41.61 | 2020-2024 | Yutiq, Iluvien |
| Coherus Oncology, INC. | $35.48 | 2023 | |
| Ocular Therapeutix, INC. | $35.13 | 2023 | Dextenza |
| Oyster Point Pharma, INC. | $18.82 | 2022 | |
| Astellas Pharma US INC | $17.37 | 2025 | Izervay |
| Notal Vision, INC. | $17.19 | 2024 | Foresee Home |
| Smith+Nephew, INC. | $13.57 | 2024 | Grafix Pl |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.